5-[7-(2-cyclopropylethylamino)-1-fluoro-3-hydroxy-2-naphthyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one

ID: ALA5076419

PubChem CID: 155103195

Max Phase: Preclinical

Molecular Formula: C17H18FN3O4S

Molecular Weight: 379.41

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C1CN(c2c(O)cc3ccc(NCCC4CC4)cc3c2F)S(=O)(=O)N1

Standard InChI:  InChI=1S/C17H18FN3O4S/c18-16-13-8-12(19-6-5-10-1-2-10)4-3-11(13)7-14(22)17(16)21-9-15(23)20-26(21,24)25/h3-4,7-8,10,19,22H,1-2,5-6,9H2,(H,20,23)

Standard InChI Key:  VILXHPHHLYDHSF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
    9.7655  -17.3647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.5655  -17.5813    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   10.3531  -16.7802    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9227  -18.8353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9216  -19.6625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6363  -20.0754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6345  -18.4226    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3499  -18.8317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3506  -19.6584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0659  -20.0692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7808  -19.6546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7760  -18.8247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0602  -18.4175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4870  -18.4055    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.2426  -18.7364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7908  -18.1200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3740  -17.4081    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.6117  -18.2013    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0558  -17.5926    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.4967  -20.0643    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.2082  -18.4230    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4940  -18.8356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7795  -18.4234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0652  -18.8359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2392  -18.8368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6518  -19.5512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17  2  1  0
  2 14  1  0
 12 14  1  0
 16 18  2  0
 13 19  1  0
 11 20  1  0
  4 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 25 24  1  0
 26 25  1  0
 24 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5076419

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 379.41

Molecular Weight (Monoisotopic): 379.1002

AlogP: 2.08

#Rotatable Bonds: 5

Polar Surface Area: 98.74

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.72

CX Basic pKa: 4.78

CX LogP: 0.70

CX LogD: 0.26

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.74

Np Likeness Score: -0.61

References

1. Abdel-Magid AF..  (2022)  The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.,  13  (1.0): [PMID:35059117] [10.1021/acsmedchemlett.1c00678]

Source

Source(1):

• Scientific Literature